Live from the NIH registry
Studies recruiting near Waterbury right now
Top 25 of 1,145 recruiting studies, sorted by proximity — each links to its official registry page
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Yale University — New Haven, Connecticut (18.2 mi)
· Sponsor: National Cancer Institute (NCI)
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
HER2-positive Metastatic Breast Cancer
N/A
Observational 200 participants sought
Smilow Cancer Hospital-Waterbury Care Center — Waterbury, Connecticut (0.8 mi)
· Sponsor: Abramson Cancer Center at Penn Medicine
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis
Phase 2
Interventional 168 participants sought
DaVita Clinical Research — Middlebury, Connecticut (5.2 mi)
· Sponsor: R1 Therapeutics
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
N/A
Interventional 400 participants sought
Yale University School of Medicine — New Haven, Connecticut (18.2 mi)
· Sponsor: Medtronic MiniMed, Inc.
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Smilow Cancer Hospital-Waterbury Care Center — Waterbury, Connecticut (0.8 mi)
· Sponsor: SWOG Cancer Research Network
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
N/A
Observational 30 participants sought
Yale School Of Medicine — New Haven, Connecticut (18.2 mi)
· Sponsor: Takeda
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Yale-New Haven Hospital-Yale Cancer Center — New Haven, Connecticut (18.2 mi)
· Sponsor: Relay Therapeutics, Inc.
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 3
Interventional 450 participants sought
Yale-New Haven Hospital — New Haven, Connecticut (18.2 mi)
· Sponsor: Eli Lilly and Company
Longitudinal Neural Fingerprinting of Opioid-use Trajectories
Opioid Use Disorder
N/A
Interventional 10 participants sought
MRRC at The Anlyan Center — New Haven, Connecticut (18.2 mi)
· Sponsor: Yale University
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Phase 4
Interventional 6,000 participants sought
Nuvance Health- Danbury Hospital — Danbury, Connecticut (24.4 mi)
· Sponsor: Duke University
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Phase 2
Interventional 50 participants sought
Yale University — New Haven, Connecticut (18.2 mi)
· Sponsor: Noffar Bar
Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing
Heart Failure
Phase 4
Interventional 20 participants sought
Yale University — New Haven, Connecticut (18.2 mi)
· Sponsor: Yale University
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Neuroblastoma
Phase 2
Interventional 93 participants sought
Connecticut Children's Hospital — Hartford, Connecticut (23.0 mi)
· Sponsor: Giselle Sholler
MMA Embolization for Refractory Chronic Migraine
Migraine Disorders
N/A
Interventional 70 participants sought
Hartford Hospital — Hartford, Connecticut (23.0 mi)
· Sponsor: Cerenovus, Part of DePuy Synthes Products, Inc.
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Colitis Ulcerative
Phase 2
Interventional 204 participants sought
Bristol Hospital- Site Number : 8400017 — Bristol, Connecticut (9.0 mi)
· Sponsor: Sanofi
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
N/A
Observational 3,000 participants sought
Yale University — New Haven, Connecticut (18.2 mi)
· Sponsor: Duke University
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
Pulmonary Invasive Fungal Infections, Pulmonary Invasive Aspergillosis
N/A
Observational 400 participants sought
Yale University — New Haven, Connecticut (18.2 mi)
· Sponsor: Arkansas Children's Hospital Research Institute
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
Phase 3
Interventional 510 participants sought
Smilow Cancer Hospital-Waterbury Care Center — Waterbury, Connecticut (0.8 mi)
· Sponsor: SWOG Cancer Research Network
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
Healthy Volunteer Study, Healthy Adults
Phase 1
Interventional 139 participants sought
Pfizer Clinical Research Unit - New Haven — New Haven, Connecticut (18.2 mi)
· Sponsor: Pfizer
Alcohol-ROC-Training
Binge Drinking, Heavy Drinking
N/A
Interventional 177 participants sought
Yale University — New Haven, Connecticut (18.2 mi)
· Sponsor: Yale University
Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
Primary Mitochondrial Disease
Phase 2
Interventional 180 participants sought
Yale University School of Medicine — New Haven, Connecticut (18.2 mi)
· Sponsor: Pharming Technologies B.V.
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Ovarian Cancer Recurrent
Phase 1, Phase 2
Interventional 460 participants sought
Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019) — New Haven, Connecticut (18.2 mi)
· Sponsor: Merck Sharp & Dohme LLC
The ArtixASCEND Study
Acute Lower Limb Arterial Occlusion
N/A
Interventional 250 participants sought
Yale University — New Haven, Connecticut (18.2 mi)
· Sponsor: Inari Medical
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
HER2/Neu+ Uterine Serous Carcinoma
Phase 2
Interventional 50 participants sought
Yale New Haven Hospital — New Haven, Connecticut (18.2 mi)
· Sponsor: Yale University
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Solid Tumor Cancer, Locally Advanced
Phase 1, Phase 2
Interventional 480 participants sought
Avenzo Therapeutics Recruiting Site — New Haven, Connecticut (18.2 mi)
· Sponsor: Avenzo Therapeutics, Inc.